A Bruton tyrosine kinase (BTK) inhibitor, that blocks BTK-mediated signaling and activation of the macrophage, was used to treat patients with COVID-19 with promising results as a potential therapeutic strategy. The gene discussed is BTK; the disease is COVID-19.